Cited by 245Pharmacogenetics and Drug MetabolismDrug-Induced Hepatotoxicity and ProtectionDrug Transport and Resistance Mechanisms

The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.

Human Hepatic Flavin-Containing Monooxygenases 1 (FMO1) and 3 (FMO3) Developmental Expression

Koukouritaki, Sevasti B, Simpson, Pippa, Yeung, Catherine K, Rettie, Allan E, Hines, Ronald N·2002·Pediatric Research

DOI 10.1203/00006450-200202000-00018

Open this paper in CoChat — free account

Abstract

The flavin-containing monooxygenases (FMOs) are important for the metabolism of numerous therapeutics and toxicants. Six mammalian FMO genes (FMO1-6) have been identified, each exhibiting developmental and tissue- and species-specific expression patterns. Previous studies demonstrated that human hepatic FMO1 is restricted to the fetus whereas FMO3 is the major adult isoform. These studies failed to describe temporal expression patterns, the precise timing of the FMO1/FMO3 switch, or potential control mechanisms. To address these questions, FMO1 and FMO3 were quantified in microsomal fractions from 240 human liver samples representing ages from 8 wk gestation to 18 y using Western blotting. FMO1 expression was highest in the embryo (8-15 wk gestation; 7.8 +/- 5.3 pmol/mg protein). Low levels of FMO3 expression also were detectable in the embryo, but not in the fetus. FMO1 suppression occurred within 3 d postpartum in a process tightly coupled to birth, but not gestational age. The onset of FMO3 expression was highly variable, with most individuals failing to express this isoform during the neonatal period. FMO3 was detectable in most individuals by 1-2 y of age and was expressed at intermediate levels until 11 y (12.7 +/- 8.0 pmol/mg protein). These data suggest that birth is necessary, but not sufficient for the onset of FMO3 expression. A gender-independent increase in FMO3 expression was observed from 11 to 18 y of age (26.9 +/- 8.6 pmol/mg protein). Finally, 2- to 20-fold interindividual variation in FMO1 and FMO3 protein levels were observed, depending on the age bracket.

Integrity signals

Registry

Crossref · 10.1203/00006450-200202000-00018

Cites

66 of 66 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4
LAEMMLI, U. K. (1970) · Nature · doi:10.1038/227680a0 · Cited by 249,961
Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.
Towbin, H., Staehelin, T., & Gordon, J. (1979) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.76.9.4350 · Cited by 53,218
Measurement of protein using bicinchoninic acid
Smith, P. K., Krohn, R. I., Hermanson, G. T., Mallia, A. K., Gartner, F. H., Provenzano, M. D., Fujimoto, E. K., Goeke, N. M., Olson, B. J., & Klenk, D. C. (1985) · Analytical Biochemistry · doi:10.1016/0003-2697(85)90442-7 · Cited by 18,482
Expression of CYP3A in the Human Liver — Evidence that the Shift between CYP3A7 and CYP3A4 Occurs Immediately After Birth
Lacroix, D. A., Sonnier, M., Moncion, A., Chéron, G., & Cresteil, T. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.00625.x · Cited by 537
Glucuronidation in Humans
de Wildt, S. N., KEARNS, G., Leeder, J. S., & van den Anker, J. N. (1999) · Clinical Pharmacokinetics · doi:10.2165/00003088-199936060-00005 · Cited by 392
Isoform specificity of trimethylamine N-oxygenation by human flavin-containing monooxygenase (FMO) and P450 enzymes
Lang, D., Yeung, C., Peter, R., Ibarra, C., Gasser, R., Itagaki, K., Philpot, R., & Rettie, A. (1998) · Biochemical Pharmacology · doi:10.1016/s0006-2952(98)00218-4 · Cited by 303
Self-citation
Missense mutation in flavin-containing mono-oxygenase 3 gene, FMO3, underlies fish-odour syndrome
Dolphin, C. T., Janmohamed, A., Smith, R. L., Shephard, E. A., & Phillips, L. R. (1997) · Nature Genetics · doi:10.1038/ng1297-491 · Cited by 284
Effects of Freezing, Thawing, and Storing Human Liver Microsomes on Cytochrome P450 Activity
Pearce, R. E., McIntyre, C. J., Madan, A., Sanzgiri, U. Y., Draper, A. J., Bullock, P. L., Cook, D. C., Burton, L. A., Latham, J., Nevins, C., et al. (1996) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1996.0294 · Cited by 253
Recent Studies on the Structure and Function of Multisubstrate Flavin-Containing Monooxygenases
Ziegler, D. M. (1993) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.33.040193.001143 · Cited by 248
Microsomal Flavin-Containing Monooxygenase: Oxygenation of Nucleophilic Nitrogen and Sulfur Compounds
Ziegler, D. M. (1980) · Elsevier eBooks · doi:10.1016/b978-0-12-380001-5.50015-3 · Cited by 234

Show all 66 references

Research works printed but not linked: 15

Clement B, 1993, Drug Metab Dispos, 21, 24
Cashman JR, 1993, Drug Metab Dispos, 21, 587
Frederick CB, 1982, Cancer Res, 42, 2671
Cashman JR, 1986, Mol Pharmacol, 29, 163
Tynes RE, 1987, Mol Pharmacol, 31, 569
Shehin-Johnson SE, 1995, J Pharmacol Exp Ther, 272, 1293
Yeung CK, 2000, Drug Metab Dispos, 28, 1107
Hines RN, 2001, Drug Metab Dispos, 29, 623
Sadeque AJM, 1992, Drug Metab Dispos, 20, 832
Duffel MW, 1981, Mol Pharmacol, 19, 134
Yang H-YL, 1994, Mol Pharmacol, 46, 922
Devereux TR, 1975, Drug Metab Dispos, 3, 254
Larsen-Su S, 1996, Drug Metab Dispos, 24, 927
Park C-S, 1999, Pharmacogenetics, 9, 155
Zschocke J, 1999, Lancet, 354, 834

Sorted by citations

Clinical biomarkers in drug discovery and development
Frank, R., & Hargreaves, R. J. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1130 · Cited by 807
Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism
Krueger, S. K., & Williams, D. E. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.01.001 · Cited by 570
Trimethylamine N -Oxide, the Microbiome, and Heart and Kidney Disease
Zeisel, S. H., & Warrier, M. (2017) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071816-064732 · Cited by 475
The ontogeny of drug metabolism enzymes and implications for adverse drug events
Hines, R. N. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.02.005 · Cited by 408
Self-citation
Developmental Expression of the Major Human Hepatic CYP3A Enzymes
Stevens, J. C., Hines, R. N., Gu, C., Koukouritaki, S. B., Manro, J. R., Tandler, P. J., & Zaya, M. J. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.054841 · Cited by 368
Self-citation
Trimethylamine and Trimethylamine N-Oxide, a Flavin-Containing Monooxygenase 3 (FMO3)-Mediated Host-Microbiome Metabolic Axis Implicated in Health and Disease
Fennema, D., Phillips, I. R., & Shephard, E. A. (2016) · Drug Metabolism and Disposition · doi:10.1124/dmd.116.070615 · Cited by 355
The Ontogeny of Human Drug-Metabolizing Enzymes: Phase I Oxidative Enzymes
Hines, R. N., & McCarver, D. G. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.300.2.355 · Cited by 364
Self-citation
Developmental Pharmacokinetics in Pediatric Populations
Lu, H., & Rosenbaum, S. (2014) · The Journal of Pediatric Pharmacology and Therapeutics · doi:10.5863/1551-6776-19.4.262 · Cited by 358
HUMAN FLAVIN-CONTAINING MONOOXYGENASES
Cashman, J. R., & Zhang, J. (2006) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.46.120604.141043 · Cited by 333
Developmental Expression of Human Hepatic CYP2C9 and CYP2C19
Koukouritaki, S. B., Manro, J. R., Marsh, S. A., Stevens, J. C., Rettie, A. E., McCarver, D. G., & Hines, R. N. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.060137 · Cited by 327
Self-citation
Metabolism of Xenobiotics of Human Environments
Croom, E. L. (2012) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-415813-9.00003-9 · Cited by 258
Impact of endocrine-disrupting compounds (EDCs) on female reproductive health
Fowler, P., Bellingham, M., Sinclair, K. D., Evans, N. P., Pocar, P., Fischer, B., Schaedlich, K., Schmidt, J., Amezaga, M. R., Bhattacharya, S., et al. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.10.021 · Cited by 228
Consensus statement: evaluation of new and existing therapeutics for pediatric multiple sclerosis
Chitnis, T., Tenembaum, S. N., Banwell, B., Krupp, L., Pohl, D., Rostasy, K. M., Yeh, E. A., Быкова, О. В., Wassmer, E., Tardieu, M., et al. (2011) · Multiple Sclerosis Journal · doi:10.1177/1352458511430704 · Cited by 219
Ontogeny of drug metabolizing enzymes in the neonate
Blake, M. J., Castro, L., Leeder, J. S., & Kearns, G. L. (2005) · Seminars in Fetal and Neonatal Medicine · doi:10.1016/j.siny.2004.11.001 · Cited by 200
Developmental expression of drug metabolizing enzymes: impact on disposition in neonates and young children.
Hines, R. (2013) · International journal of pharmaceutics · doi:10.1016/j.ijpharm.2012.05.079 · Cited by 160
Self-citation
Organization and evolution of the flavin-containing monooxygenase genes of human and mouse
Hernandez, D., Janmohamed, A., Chandan, P., Phillips, I. R., & Shephard, E. A. (2004) · Pharmacogenetics · doi:10.1097/00008571-200402000-00006 · Cited by 173
Human Hepatic CYP2E1 Expression during Development
Johnsrud, E. K., Koukouritaki, S. B., Divakaran, K., Brunengraber, L. L., Hines, R. N., & McCarver, D. G. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.053124 · Cited by 169
Self-citation
Developmental Changes in Human Liver CYP2D6 Expression
Stevens, J. C., Marsh, S. A., Zaya, M. J., Regina, K. J., Divakaran, K., Le, M., & Hines, R. N. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.021873 · Cited by 163
Self-citation
Differences in absorption, distribution, metabolism and excretion of xenobiotics between the paediatric and adult populations
Benedetti, M. S., Whomsley, R., & Baltes, E. (2005) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.1.3.447 · Cited by 155
QUANTITATIVE ANALYSIS OF FMO GENE mRNA LEVELS IN HUMAN TISSUES
Zhang, J., & Cashman, J. R. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.006171 · Cited by 144
Flavin-containing monooxygenases: mutations, disease and drug response
Phillips, I. R., & Shephard, E. A. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.03.004 · Cited by 141
Isolation of pigment cell specific genes in the sea urchin embryo by differential macroarray screening
Calestani, C., Rast, J. P., & Davidson, E. H. (2003) · Development · doi:10.1242/dev.00647 · Cited by 137
Paediatric oral biopharmaceutics: Key considerations and current challenges
Batchelor, H. K., Fotaki, N., & Klein, S. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.10.006 · Cited by 141
Cell-, tissue-, sex- and developmental stage-specific expression of mouse flavin-containing monooxygenases (Fmos)
Janmohamed, A., Hernandez, D., Phillips, I. R., & Shephard, E. A. (2004) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.02.036 · Cited by 121
Drug metabolism by flavin-containing monooxygenases of human and mouse
Phillips, I. R., & Shephard, E. A. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1239718 · Cited by 111
Xenobiotic metabolism gene expression in the EpiDerm™ in vitro 3D human epidermis model compared to human skin
Hu, T., Khambatta, Z. S., Hayden, P. J., Bolmarcich, J., Binder, R. L., Robinson, M. K., Carr, G. J., Tiesman, J. P., Jarrold, B. B., Osborne, R., et al. (2010) · Toxicology in Vitro · doi:10.1016/j.tiv.2010.03.013 · Cited by 110
Interindividual Differences of Human Flavin-Containing Monooxygenase 3: Genetic Polymorphisms and Functional Variation
Cashman, J. R., & Zhang, J. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.10.1043 · Cited by 109
Developmental Expression of Aryl, Estrogen, and Hydroxysteroid Sulfotransferases in Pre- and Postnatal Human Liver
Duanmu, Z., Weckle, A. L., Koukouritaki, S. B., Hines, R. N., Falany, J. L., Falany, C. N., Kocarek, T. A., & Runge‐Morris, M. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.093633 · Cited by 106
Self-citation
Human hepatic CYP2B6 developmental expression: The impact of age and genotype
Croom, E. L., Stevens, J. C., Hines, R. N., Wallace, A. D., & Hodgson, E. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.03.029 · Cited by 98
Self-citation
Involvement of enzymes other than CYPs in the oxidative metabolism of xenobiotics
Benedetti, M. S., Whomsley, R., & Baltes, E. (2006) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2.6.895 · Cited by 96
Pediatric Pharmacokinetic Data: Implications for Environmental Risk Assessment for Children
Ginsberg, G., Hattis, D. B., Miller, R. K., & Sonawane, B. R. (2004) · PEDIATRICS · doi:10.1542/peds.113.s3.973 · Cited by 96
Trimethylaminuria: causes and diagnosis of a socially distressing condition.
Mackay, R. J., McEntyre, C. J., Henderson, C., Lever, M., & George, P. M. (2011) · Europe PMC (PubMed Central) · Cited by 94
Indoles Derived From Glucobrassicin: Cancer Chemoprevention by Indole-3-Carbinol and 3,3'-Diindolylmethane
Williams, D. E. (2021) · Frontiers in Nutrition · doi:10.3389/fnut.2021.734334 · Cited by 92
Epirubicin Glucuronidation and UGT2B7 Developmental Expression
Zaya, M. J., Hines, R. N., & Stevens, J. C. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.011387 · Cited by 92
Self-citation
Alternative Processing of the Human FMO6 Gene Renders Transcripts Incapable of Encoding a Functional Flavin-Containing Monooxygenase
Hines, R. N., Hopp, K. A., Franco, J., Saeian, K., & Begun, F. P. (2002) · Molecular Pharmacology · doi:10.1124/mol.62.2.320 · Cited by 88
Self-citation
Flavin-Containing Monooxygenase 1 Catalyzes the Production of Taurine from Hypotaurine
Veeravalli, S., Phillips, I. R., Freire, R. T., Varshavi, D., Everett, J. R., & Shephard, E. A. (2020) · Drug Metabolism and Disposition · doi:10.1124/dmd.119.089995 · Cited by 85
Novel insights into the complex pharmacokinetics of voriconazole: a review of its metabolism
Schulz, J., Kluwe, F., Mikus, G., Michelet, R., & Kloft, C. (2019) · Drug Metabolism Reviews · doi:10.1080/03602532.2019.1632888 · Cited by 83
Flavin-containing monooxygenases in aging and disease: Emerging roles for ancient enzymes
Rossner, R., Kaeberlein, M. R., & Leiser, S. F. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.r117.779678 · Cited by 81
Role of flavin-containing monooxgenase in drug development
Cashman, J. R. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250802522188 · Cited by 79
Human Kidney Flavin-Containing Monooxygenases and Their Potential Roles in Cysteine S-Conjugate Metabolism and Nephrotoxicity
Krause, R. J., Lash, L. H., & Elfarra, A. A. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.042911 · Cited by 79
A comparison of neurocognitive functioning in children previously randomized to dexamethasone or prednisone in the treatment of childhood acute lymphoblastic leukemia
Kadan‐Lottick, N. S., Brouwers, P. Y., Breiger, D., Kaleita, T. A., Dziura, J., Liu, H., Chen, L., Nicoletti, M., Stork, L. C., Bostrom, B., et al. (2009) · Blood · doi:10.1182/blood-2008-12-186502 · Cited by 78
Mammalian flavin-containing monooxygenase (FMO) as a source of hydrogen peroxide
Siddens, L. K., Krueger, S. K., Henderson, M. C., & Williams, D. E. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.02.006 · Cited by 75
Specific features of pharmacokinetics in children
Matalová, P., Urbánek, K., & Anzenbacher, P. (2016) · Drug Metabolism Reviews · doi:10.3109/03602532.2015.1135941 · Cited by 73
Trimethylamine N -oxide: heart of the microbiota–CVD nexus?
Naghipour, S., Cox, A. J., Peart, J. N., Toit, E. F. D., & Headrick, J. P. (2020) · Nutrition Research Reviews · doi:10.1017/s0954422420000177 · Cited by 77
The implications of polymorphisms in mammalian flavin-containing monooxygenases in drug discovery and development
Cashman, J. R. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03136-8 · Cited by 71
Metabolism of the anti-tuberculosis drug ethionamide by mouse and human FMO1, FMO2 and FMO3 and mouse and human lung microsomes
Henderson, M. C., Siddens, L. K., Morré, J. T., Krueger, S. K., & Williams, D. E. (2008) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2008.09.017 · Cited by 71
Flavin-containing monooxygenase 3 (FMO3): genetic variants and their consequences for drug metabolism and disease
Phillips, I. R., & Shephard, E. A. (2019) · Xenobiotica · doi:10.1080/00498254.2019.1643515 · Cited by 72
TWO NEW POLYMORPHISMS OF THE FMO3 GENE IN CAUCASIAN AND AFRICAN-AMERICAN POPULATIONS: COMPARATIVE GENETIC AND FUNCTIONAL STUDIES
Lattard, V., Zhang, J., Tran, Q., Furnes, B., Schlenk, D., & Cashman, J. R. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.7.854 · Cited by 71
Discovery of Novel Flavin-Containing Monooxygenase 3 (FMO3) Single Nucleotide Polymorphisms and Functional Analysis of Upstream Haplotype Variants
Koukouritaki, S. B., Poch, M. T., Cabacungan, E., McCarver, D. G., & Hines, R. N. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.012062 · Cited by 69
Self-citation
Identification and Functional Analysis of Common Human Flavin-Containing Monooxygenase 3 Genetic Variants
Koukouritaki, S. B., Poch, M. T., Henderson, M. C., Siddens, L. K., Krueger, S. K., VanDyke, J. E., Williams, D. E., Pajewski, N. M., Wang, T., & Hines, R. N. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.112268 · Cited by 69
Self-citation
Identification of Novel Variants of the Flavin-Containing Monooxygenase Gene Family in African Americans
Furnes, B., Feng, J., Sommer, S. S., & Schlenk, D. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.2.187 · Cited by 67
Maternal Smoking and Fetal Sex Significantly Affect Metabolic Enzyme Expression in the Human Fetal Liver
O’Shaughnessy, P. J., Monteiro, A., Bhattacharya, S., & Fowler, P. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1437 · Cited by 70
Reaction Phenotyping: Current Industry Efforts to Identify Enzymes Responsible for Metabolizing Drug Candidates
Harper, T. W., & Brassil, P. J. (2008) · The AAPS Journal · doi:10.1208/s12248-008-9019-6 · Cited by 64
Sources of Interindividual Variability
Thummel, K. E., & Lin, Y. S. (2014) · Methods in molecular biology · doi:10.1007/978-1-62703-758-7_17 · Cited by 65
Role of biokinetics in risk assessment of drugs and chemicals in children
de Zwart, L. L., Haenen, H. E. M. G., Versantvoort, C. H. M., Wolterink, G., van Engelen, J. G. M., & Sips, A. J. A. M. (2004) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2004.02.006 · Cited by 63
Childhood Brain Tumors, Residential Insecticide Exposure, and Pesticide Metabolism Genes
Nielsen, S. S., McKean‐Cowdin, R., Farin, F. M., Holly, E. A., Preston‐Martin, S., & Mueller, B. A. (2009) · Environmental Health Perspectives · doi:10.1289/ehp.0901226 · Cited by 62
Human Flavin-Containing Monooxygenase (form 3): Polymorphisms and Variations In Chemical Metabolism
Cashman, J. R. (2002) · Pharmacogenomics · doi:10.1517/14622416.3.3.325 · Cited by 60
Flavin-Containing Monooxygenase Genetic Polymorphism: Impact on Chemical Metabolism and Drug Development
Koukouritaki, S. B., & Hines, R. N. (2005) · Pharmacogenomics · doi:10.2217/14622416.6.8.807 · Cited by 60
Self-citation
Ontogeny of mammalian metabolizing enzymes in humans and animals used in toxicological studies
Saghir, S. A., Khan, S. A., & McCoy, A. T. (2012) · Critical Reviews in Toxicology · doi:10.3109/10408444.2012.674100 · Cited by 59
The Biochemistry of Drug Metabolism – An Introduction
Krämer, S. D., & Testa, B. (2008) · Chemistry & Biodiversity · doi:10.1002/cbdv.200890214 · Cited by 59
Cytochrome P450 and flavin-containing monooxygenase families: age-dependent differences in expression and functional activity
Zane, N. R., Chen, Y., Wang, M. Z., & Thakker, D. R. (2017) · Pediatric Research · doi:10.1038/pr.2017.226 · Cited by 57
The Role of Flavin-Containing Monooxygenase (FMO) in the Metabolism of Tamoxifen and Other Tertiary Amines
Krueger, S. K., VanDyke, J. E., Williams, D. E., & Hines, R. N. (2006) · Drug Metabolism Reviews · doi:10.1080/03602530600569919 · Cited by 57
Self-citation
Evaluation of Xenobiotic N- and S-Oxidation by Variant Flavin-Containing Monooxygenase 1 (FMO1) Enzymes
Furnes, B. (2004) · Toxicological Sciences · doi:10.1093/toxsci/kfh079 · Cited by 56
Age-Dependent Human Hepatic Carboxylesterase 1 (CES1) and Carboxylesterase 2 (CES2) Postnatal Ontogeny
Hines, R. N., Simpson, P. M., & McCarver, D. G. (2016) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.068957 · Cited by 56
Self-citation
Psychosocial support of the pediatric cancer patient: Lessons learned over the past 50 years
Askins, M. A., & Moore, B. D. (2008) · Current Oncology Reports · doi:10.1007/s11912-008-0072-1 · Cited by 54
Genetic and Nongenetic Factors Associated with Protein Abundance of Flavin-Containing Monooxygenase 3 in Human Liver
Xu, M., Bhatt, D. K., Yeung, C. K., Claw, K. G., Chaudhry, A. S., Gaedigk, A., Pearce, R. E., Broeckel, U., Gaedigk, R., Nickerson, D. A., et al. (2017) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.243113 · Cited by 54
Self-citation
Essentials for starting a pediatric clinical study (1): Pharmacokinetics in children
Yokoi, T. (2009) · The Journal of Toxicological Sciences · doi:10.2131/jts.34.sp307 · Cited by 49
Human arylacetamide deacetylase hydrolyzes ketoconazole to trigger hepatocellular toxicity
Fukami, T., Iida, A., Konishi, K., & Nakajima, M. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.07.007 · Cited by 49
Human Hepatic UGT2B15 Developmental Expression
Divakaran, K., Hines, R. N., & McCarver, D. G. (2014) · Toxicological Sciences · doi:10.1093/toxsci/kfu126 · Cited by 47
Self-citation
Model‐Based Drug–Drug Interaction Extrapolation Strategy From Adults to Children: Risdiplam in Pediatric Patients With Spinal Muscular Atrophy
Cleary, Y., Gertz, M., Grimsey, P., Günther, A., Heinig, K., Ogungbenro, K., Aarons, L. J., Galetin, A., & Kletzl, H. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2384 · Cited by 46
The phenotype of a flavin-containing monooyxgenase knockout mouse implicates the drug-metabolizing enzyme FMO1 as a novel regulator of energy balance
Veeravalli, S., Omar, B. A., Houseman, L., Hancock, M., Malagon, S. G. G., Scott, F. H., Janmohamed, A., Phillips, I. R., & Shephard, E. A. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.04.007 · Cited by 44
Human Flavin-Containing Monooxygenase 2.1 Catalyzes Oxygenation of the Antitubercular Drugs Thiacetazone and Ethionamide
Francois, A. A., Nishida, C. R., de Montellano, P. R. O., Phillips, I. R., & Shephard, E. A. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.024158 · Cited by 45
Recent advances in the ontogeny of drug disposition
Chapron, B. D., Chapron, A., & Leeder, J. S. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14821 · Cited by 46
Perinatal Hypercholesterolemia Exacerbates Atherosclerosis Lesions in Offspring by Altering Metabolism of Trimethylamine-N-Oxide and Bile Acids
Trenteseaux, C., Gaston, A., Aguesse, A., Poupeau, G., de Coppet, P., Andriantsitohaina, R., Khallou‐Laschet, J., Amarger, V., Krempf, M., Nobécourt, E., et al. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.309923 · Cited by 43
Genetic Variability at the Human FMO1 Locus: Significance of a Basal Promoter Yin Yang 1 Element Polymorphism (FMO1*6)
Hines, R. N., Luo, Z., Hopp, K. A., Cabacungan, E., Koukouritaki, S. B., & McCarver, D. G. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.053686 · Cited by 43
Self-citation
Benzydamine N-oxygenation as an index for flavin-containing monooxygenase activity and benzydamine N-demethylation by cytochrome P450 enzymes in liver microsomes from rats, dogs, monkeys, and humans
Taniguchi-Takizawa, T., Shimizu, M., Kume, T., & Yamazaki, H. (2014) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2014.09.006 · Cited by 42
Use of dietary phytochemicals for inhibition of trimethylamine N-oxide formation
Iglesias‐Carres, L., Hughes, M. D., Steele, C. N., Ponder, M. A., Davy, K. P., & Neilson, A. P. (2021) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2021.108600 · Cited by 43
Developmental Changes of Aldehyde Oxidase Activity in Young Japanese Children
Tayama, Y., Miyake, K., Sugihara, K., Kitamura, S., Kobayashi, M., Morita, S., Ohta, S., & Kihira, K. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100078 · Cited by 42
Developmental and tissue-specific expression of human flavin-containing monooxygenases 1 and 3
Hines, R. N. (2006) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2.1.41 · Cited by 42
Self-citation
Stop codon mutations in the flavin-containing monooxygenase 3 (FMO3) gene responsible for trimethylaminuria in a Japanese population
Yamazaki, H., Fujita, H., Gunji, T., Zhang, J., Kamataki, T., Cashman, J. R., & Shimizu, M. (2006) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2006.08.008 · Cited by 40
Genetic Polymorphisms of Human Flavin-Containing Monooxygenase 3: Implications for Drug Metabolism and Clinical Perspectives
Hisamuddin, I. M., & Yang, V. W. (2007) · Pharmacogenomics · doi:10.2217/14622416.8.6.635 · Cited by 38
Alternative promoters and repetitive DNA elements define the species-dependent tissue-specific expression of theFMO1genes of human and mouse
Shephard, E. A., Chandan, P., Stevanovic-Walker, M., Edwards, M., & Phillips, I. R. (2007) · Biochemical Journal · doi:10.1042/bj20070523 · Cited by 38
Metabolism of Toxicants
Rose, R. L., & Hodgson, E. (2004) · doi:10.1002/0471646776.ch7 · Cited by 38
HepaSH cells: Experimental human hepatocytes with lesser inter-individual variation and more sustainable availability than primary human hepatocytes
Uehara, S., Higuchi, Y., Yoneda, N., Ito, R., Takahashi, T., Murayama, N., Yamazaki, H., Murai, K., Hikita, H., Takehara, T., et al. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.04.054 · Cited by 37
Effect of Flavin-Containing Monooxygenase Genotype, Mouse Strain, and Gender on Trimethylamine N-oxide Production, Plasma Cholesterol Concentration, and an Index of Atherosclerosis
Veeravalli, S., Karu, K., Scott, F. H., Fennema, D., Phillips, I. R., & Shephard, E. A. (2017) · Drug Metabolism and Disposition · doi:10.1124/dmd.117.077636 · Cited by 38
The Flavin-Containing Monoooxygenases (FMOs): Genetic Variation and its Consequences for the Metabolism of Therapeutic Drugs
Phillips, I. R., Francois, A. A., & Shephard, E. A. (2007) · Current Pharmacogenomics · doi:10.2174/157016007782793683 · Cited by 37
Clinical utility gene card for: Trimethylaminuria – update 2014
Shephard, E. A., Treacy, E. P., & Phillips, I. R. (2014) · European Journal of Human Genetics · doi:10.1038/ejhg.2014.226 · Cited by 37
Molecular and functional characterization of flavin-containing monooxygenases in cynomolgus macaque
Uno, Y., Shimizu, M., & Yamazaki, H. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.04.012 · Cited by 36
Non-cytochrome P450-mediated bioactivation and its toxicological relevance
Gan, J., Ma, S., & Zhang, D. (2016) · Drug Metabolism Reviews · doi:10.1080/03602532.2016.1225756 · Cited by 38
Developmental Expression of the Cytosolic Sulfotransferases in Human Liver
Dubaisi, S., Caruso, J. A., Gaedigk, R., Vyhlidal, C. A., Smith, P. C., Hines, R. N., Kocarek, T. A., & Runge‐Morris, M. (2019) · Drug Metabolism and Disposition · doi:10.1124/dmd.119.086363 · Cited by 35
Self-citation
Roles of selected non-P450 human oxidoreductase enzymes in protective and toxic effects of chemicals: review and compilation of reactions
Rendić, S., Crouch, R. D., & Guengerich, F. P. (2022) · Archives of Toxicology · doi:10.1007/s00204-022-03304-3 · Cited by 37
Molecular evolution and balancing selection in the flavin-containing monooxygenase 3 gene (FMO3)
Allerston, C. K., Shimizu, M., Fujieda, M., Shephard, E. A., Yamazaki, H., & Phillips, I. R. (2007) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e328256b198 · Cited by 33
The Biochemistry of Drug Metabolism – An Introduction
Krämer, S. D., & Testa, B. (2009) · Chemistry & Biodiversity · doi:10.1002/cbdv.200900233 · Cited by 34
Emerging epigenetic dynamics in gut-microglia brain axis: experimental and clinical implications for accelerated brain aging in schizophrenia
Ben‐Azu, B., del Re, E. C., VanderZwaag, J., Carrier, M., Keshavan, M. S., Khakpour, M., & Tremblay, M. (2023) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2023.1139357 · Cited by 32
RNA-Sequencing Quantification of Hepatic Ontogeny of Phase-I Enzymes in Mice
Peng, L., Cui, J. Y., Yoo, B., Gunewardena, S., Lü, H., Klaassen, C. D., & Zhong, X. (2013) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.054635 · Cited by 32
Functional activity of the mouse flavin‐containing monooxygenase forms 1, 3, and 5
Zhang, J., Cerny, M. A., Lawson, M., Mosadeghi, R., & Cashman, J. R. (2007) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.20176 · Cited by 32
Inter-individual Variation in Flavin-containing Monooxygenase 3 in Livers from Japanese: Correlation with Hepatic Transcription Factors
Nagashima, S., Shimizu, M., Yano, H., Murayama, N., Kumai, T., Kobayashi, S., Guengerich, F. P., & Yamazaki, H. (2009) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.24.218 · Cited by 32
Sex-specific gene expression in the BXD mouse liver
Gatti, D. M., Zhao, N., Chesler, E. J., Bradford, B. U., Shabalin, A. A., Yordanova, R., Lu, L., & Rusyn, I. (2010) · Physiological Genomics · doi:10.1152/physiolgenomics.00110.2009 · Cited by 31
Developmental variations in metabolic capacity of flavin‐containing mono‐oxygenase 3 in childhood
Shimizu, M., Denton, T. T., Kozono, M., Cashman, J. R., Leeder, J. S., & Yamazaki, H. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03876.x · Cited by 31
Principles of Drug Metabolism 1: Redox Reactions
Trager, W. F. (2007) · Elsevier eBooks · doi:10.1016/b0-08-045044-x/00119-x · Cited by 32

Authors: Koukouritaki, S. B., Simpson, P., Yeung, C. K., Rettie, A. E., & Hines, R. N.
Affiliations: Medical College of Wisconsin (US)
University of Arkansas for Medical Sciences (US)
University of Washington (US)
Corresponding author: Hines, Ronald N
ORCID: Koukouritaki, Sevasti B
Simpson, Pippa
Yeung, Catherine K
Rettie, Allan E
Hines, Ronald N
Venue: Pediatric Research
Publisher: Springer Science and Business Media LLC
Published: 2002-02
Volume: 51
Issue: 2
Pages: 236-243
ISSN: 0031-3998 (ISSN-L)
1530-0447
DOI: 10.1203/00006450-200202000-00018
OpenAlex: W2068390361
Cited by: 245
References: 66
Citations by year: 2026: 4 · 2025: 5 · 2024: 6 · 2023: 11 · 2022: 5 · 2021: 9 · 2020: 12 · 2019: 11 · 2018: 6 · 2017: 13 · 2016: 15 · 2015: 2 · 2014: 14 · 2013: 8 · 2012: 17
FWCI: 9.16
Type: journal article
Language: en
Open access: closed
Locations: Pediatric Research (publishedVersion)
PubMed (publishedVersion)
Funders: National Cancer Institute (CA53106, R01CA053106)
National Institute of General Medical Sciences (GM43511, GM-07750, T32GM007750)
Topics: Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
Keywords: flavin-containing monooxygenase, FMO1, FMO3, developmental gene expression, fetal liver, neonatal liver, age-related expression, interindividual variability, human liver microsomes, drug metabolism
MeSH terms: Adolescent, Adult, Aging, Child, Child, Preschool, Embryo, Mammalian, Female, Fetus, Gestational Age, Humans, Infant, Infant, Newborn, Isoenzymes, Liver, Male, Microsomes, Liver, Oxygenases, Gene Expression Regulation, Enzymologic, Gene Expression Regulation, Developmental

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Human Hepatic Flavin-Containing Monooxygenases 1 (FMO1) and 3 (FMO3) Developmental Expression

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks